Rigel Pharmaceuticals, Inc. (RIGL) Analysts See $-0.17 EPS

April 25, 2018 - By Winifred Garcia

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) LogoInvestors sentiment increased to 2.06 in 2017 Q4. Its up 0.67, from 1.39 in 2017Q3. It improved, as 14 investors sold Rigel Pharmaceuticals, Inc. shares while 18 reduced holdings. 22 funds opened positions while 44 raised stakes. 127.13 million shares or 21.87% more from 104.32 million shares in 2017Q3 were reported.
Price T Rowe Assoc Md holds 2.68 million shares or 0% of its portfolio. Parallax Volatility Advisers Limited Partnership holds 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) for 22,596 shares. Employees Retirement Association Of Colorado has invested 0% of its portfolio in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Citigroup Incorporated owns 178,098 shares for 0% of their portfolio. Macquarie Gru invested 0.01% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Highbridge Capital Mgmt Lc reported 108,250 shares. Susquehanna Group Ltd Liability Partnership stated it has 52,530 shares. Hudson Bay Mgmt Limited Partnership reported 1.25 million shares stake. Jane Street Gp Ltd Liability Company reported 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Royal Retail Bank Of Canada holds 0% or 2,580 shares in its portfolio. Victory Mgmt has invested 0% in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL). Bain Cap Pub Equity Mngmt Lc reported 0.09% stake. Great West Life Assurance Can reported 16,712 shares stake. Natl Bank Of America De holds 0% or 50,952 shares in its portfolio. Teachers Retirement Of The State Of Kentucky holds 70,200 shares.

Analysts expect Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to report $-0.17 EPS on May, 1.They anticipate $0.04 EPS change or 30.77 % from last quarter’s $-0.13 EPS. After having $-0.18 EPS previously, Rigel Pharmaceuticals, Inc.’s analysts see -5.56 % EPS growth. The stock increased 3.61% or $0.13 during the last trading session, reaching $3.73. About 2.39M shares traded. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has risen 9.91% since April 25, 2017 and is uptrending. It has underperformed by 1.64% the S&P500.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Ratings Coverage

Among 6 analysts covering Rigel Pharmaceuticals (NASDAQ:RIGL), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Rigel Pharmaceuticals had 15 analyst reports since November 6, 2017 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, April 4 by Jefferies. The rating was maintained by H.C. Wainwright with “Buy” on Friday, February 2. The rating was maintained by H.C. Wainwright with “Buy” on Monday, December 11. The rating was maintained by Cantor Fitzgerald on Tuesday, April 17 with “Buy”. The firm has “Buy” rating given on Monday, November 6 by H.C. Wainwright. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Tuesday, April 3. H.C. Wainwright has “Buy” rating and $6.7 target. H.C. Wainwright maintained Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rating on Wednesday, April 18. H.C. Wainwright has “Buy” rating and $800 target. On Friday, January 19 the stock rating was maintained by H.C. Wainwright with “Buy”. The stock of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) has “Buy” rating given on Tuesday, March 6 by Cantor Fitzgerald. The stock has “Outperform” rating by BMO Capital Markets on Wednesday, April 18.

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology. The company has market cap of $607.30 million. The company's clinical programs include fostamatinib, an oral spleen tyrosine kinase inhibitor, which has completed Phase III clinical program for immune thrombocytopenia purpura; and Phase II clinical study for autoimmune hemolytic anemia and IgA nephropathy. It currently has negative earnings. It is also developing two oncology product candidates, which are in Phase I and Phase II.

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.